---
title: "Barinthus in Green on Bringing Out Quarterly Numbers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284798518.md"
description: "Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported its financial results for Q1 2026, highlighting advancements in its corporate developments. CEO Bill Enright emphasized the transformative potential of a proposed combination with Clywedog, aimed at enhancing their pipeline for autoimmune and metabolic diseases. The company is also focused on the clinical development of VTP-1000 for celiac disease, with promising data from the Phase I AVALON trial. Following the announcement, BRNS shares rose by 6.5% to 63.9 cents."
datetime: "2026-04-30T15:07:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284798518.md)
  - [en](https://longbridge.com/en/news/284798518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284798518.md)
---

# Barinthus in Green on Bringing Out Quarterly Numbers

Barinthus Biotherapeutics plc (NASDAQ: BRNS) noticed its stock take on new strength early Thursday. The Germantown, Md.-based company today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation company focused on developing therapies that promote immune tolerance with curative potential.

"As we complete the first quarter of 2026, our focus remains on advancing the proposed combination with Clywedog, which we believe represents a transformative opportunity for Barinthus Bio by creating a compelling and differentiated pipeline focused on autoimmune and metabolic diseases,” said CEO Bill Enright.

"Throughout the first quarter, we continued to advance the activities necessary to complete the transaction, while also preparing for a seamless integration following closing. At the same time, our major focus is to progress the ongoing clinical development of our core asset, VTP-1000, in celiac disease. With encouraging single ascending dose data in hand from the Phase I AVALON trial and multiple ascending dose data expected in the second half of 2026, we see a clear opportunity for VTP-1000 to deliver near-term clinical milestones and to contribute to long-term shareholder value for the combined company.”

BRNS shares gained four cents, or 6.5%, to 63.9 cents.

### Related Stocks

- [BRNS.US](https://longbridge.com/en/quote/BRNS.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md)